# Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Study · id `cardio:ct-nct06415773` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06415773](<https://clinicaltrials.gov/study/NCT06415773>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06415773

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 367 participants.

## Technical summary

Registry record NCT06415773. Randomized; double masking; primary purpose treatment. Start 2024-06-04 (actual); primary completion 2025-06-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 367 participants (enrolled count; ClinicalTrials.gov record NCT06415773, source copy `cardio:ctgov-nct06415773-2026-08-03`, retrieved 2026-10-26)
- Started: 2024-06-04 (actual) (ClinicalTrials.gov record NCT06415773, source copy `cardio:ctgov-nct06415773-2026-08-03`, retrieved 2026-10-26)
- Primary completion: 2025-06-13 (actual) (ClinicalTrials.gov record NCT06415773, source copy `cardio:ctgov-nct06415773-2026-08-03`, retrieved 2026-10-26)
- Completion: 2025-07-25 (actual) (ClinicalTrials.gov record NCT06415773, source copy `cardio:ctgov-nct06415773-2026-08-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06415773, source copy `cardio:ctgov-nct06415773-2026-08-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06415773-2026-08-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
- Acronym: HARMONY
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug): HTD1801
- Intervention (Drug): Dapagliflozin
- Lead sponsor: Shenzhen HighTide Biopharmaceutical Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: Shenzhen HighTide Biopharmaceutical Ltd. (`cardio:org-shenzhen-hightide-biopharmaceutical-ltd`)

## Provenance

Content hash: b5a4b985f7df987f4408731c9f5b34ef416d10fdaeaf38d659517df80eb22032
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
